

**Form 39A [See Rule 150E(f)] Under the Drugs and Cosmetics Act 1940 and the Rules thereunder**

Sample Name #	ACELOFENAC & TIZANIDINE TABLETS 100 mg	Report No.	[REDACTED]
		Mfg. Lic. No.#	
Mfd. By#	NA		
Supplied By#	NA	Date of Receipt	16/09/2024
Submitted By Address	MEGHALAYAN MEDICAL DRUGS AND SERVICES NEW COLONY SHILLONG, DHS LAITUMKHRAH, OFFICE OF THE MANAGING DIRECTOR MMSDSL EAST	Sample Qty.#	60 TABLETS
		Batch Size#	NA
		Mfg.Date#	07/2024
Ref. No.#	N/A	Exp.Date#	06/2026
Batch No.#	MMSDSL/QC/-0476		

NS

Date of Start of Analysis : 16/09/2024

Date of Completion of Analysis : 26/09/2024

**RESULTS OF ANALYSIS**

Reference to Protocol : IHS

DESCRIPTION : Creamy white round shaped biconvex uncoated tablet scored on one side and other side plain.

S.No.	PARAMETERS/TEST	RESULTS	LIMIT		
1	IDENTIFICATION	Positive for both Aceclofenac and Tizanidine HCL			
2	AVERAGE WEIGHT	293.30 mg			
3	UNIFORMITY OF WEIGHT	Within Limit	± 5.0%		
4	ASSAY	Each uncoated tablet contains.			
COMPOSITION		RESULTS	LABEL CLAIM	LIMITS	PROTOCOL
ACECLOFENAC IP		94.25 mg	100 mg	90 to 110 mg	IHS
TIZANIDINE HCL IP		1.86 mg	2 mg	1.8 to 2.2 mg	IHS

**Remarks :** In the opinion of the undersigned, the sample referred above is of standard quality as defined in the Drugs Act 1940 and Rules made their under for the reasons given below as per:- IHS  
Sample Consume in testing.

\*\*\*\*\*END OF REPORT\*\*\*\*\*

# Represents Customer Defined Fields

Date of Issue : 13/11/2024

**Note:-**

1. Sample (s) not drawn by us unless otherwise stated.
2. Total liability of our analytical division is limited to the invoiced amount.
3. Sample will be destroyed after one month from the date of issue of test certificate unless otherwise specified.
4. Test certificate in full or parts shall not be use for promotional or publicity purpose.
5. Result given in report in related to sample tested only.